Schrodinger, the biotech startup focused on drug design and discovery, has added an additional $25M in Series E extension funding from investors that include GV, Invus, Bill Gates, Pavilion Capital, and Michael Antonov. The extension brings the total funding for the round to $110M. Founded by Richard Friesner and William Goddard in 1990, Schrodinger has now raised a total of $162M in reported equity funding. We had an exclusive interview with Shi-Yi Liu about the company’s initial Series E round – Shrodinger’s Series E funding.
Say goodbye to recruiter spam
No more recruiter spam! Eliminate wasted time of managing communications with irrelevant job positions by only getting matched with relevant jobs based on his career goals. Indeed Prime matches you with top companies which align with your career goals, technical skill set, and location preferences.